Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
- Written by PR Newswire
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or...














